placebo + tiotropium

placebo + tiotropium refers to a specific treatment arm used as a control in clinical trials, such as those conducted by Verona Pharma plc for chronic obstructive pulmonary disease (COPD). This combination involves the administration of tiotropium, a long-acting muscarinic antagonist (LAMA), alongside an inactive placebo. Tiotropium works by competitively and reversibly inhibiting M3 muscarinic receptors in the bronchial smooth muscle, leading to sustained bronchodilation and improved lung function. In the context of Verona Pharma's Phase 2 studies, this arm was used to compare the efficacy of ensifentrine (a dual PDE3/4 inhibitor) when added to standard-of-care LAMA therapy versus LAMA therapy alone (represented by placebo + tiotropium).

Other names

tiotropium bromide